AIM: To compare the effects of tamoxifen and megestrol acetate on liver proteins, androgens, and glucocorticoids during adjuvant treatment for postmenopausal breast cancer. METHODS: A subgroup of women within a large prospective multicenter trial were followed with blood sampling every 3 mo during 2 yr. Women were randomized to receive either continuous tamoxifen 40 mg/d or repeated sequential treatment with tamoxifen and megestrol acetate (MA) 160 mg/d. RESULTS: We found profound and distinct differences between the two regimens. Tamoxifen increased steroid-binding proteins (SHBG and CBG) and suppressed circulating androgens and IGF-I. In contrast, the metabolic effects of tamoxifen were clearly antagonized by MA. There was a rise in IGF-I and marked suppression of steroid-binding proteins. Levels of free testosterone were reduced by 70%. MA also caused apparent adrenal suppression. CONCLUSION: The different effects on anabolic/catabolic balance and adrenal function may relate to certain clinical effects during treatment.
RCT Entities:
AIM: To compare the effects of tamoxifen and megestrol acetate on liver proteins, androgens, and glucocorticoids during adjuvant treatment for postmenopausal breast cancer. METHODS: A subgroup of women within a large prospective multicenter trial were followed with blood sampling every 3 mo during 2 yr. Women were randomized to receive either continuous tamoxifen 40 mg/d or repeated sequential treatment with tamoxifen and megestrol acetate (MA) 160 mg/d. RESULTS: We found profound and distinct differences between the two regimens. Tamoxifen increased steroid-binding proteins (SHBG and CBG) and suppressed circulating androgens and IGF-I. In contrast, the metabolic effects of tamoxifen were clearly antagonized by MA. There was a rise in IGF-I and marked suppression of steroid-binding proteins. Levels of free testosterone were reduced by 70%. MA also caused apparent adrenal suppression. CONCLUSION: The different effects on anabolic/catabolic balance and adrenal function may relate to certain clinical effects during treatment.
Authors: I Kostoglou-Athanassiou; K Ntalles; J Gogas; C Markopoulos; V Alevizou-Terzaki; P Athanassiou; E Georgiou; C Proukakis Journal: Horm Res Date: 1997
Authors: Sharon Wayne; Marian L Neuhouser; Cornelia M Ulrich; Carol Koprowski; Charles Wiggins; Kathy B Baumgartner; Leslie Bernstein; Richard N Baumgartner; Frank Gilliland; Anne McTiernan; Rachel Ballard-Barbash Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-10-28 Impact factor: 4.254
Authors: Noel N Kim; Miljan Stankovic; Abdullah Armagan; Tulay T Cushman; Irwin Goldstein; Abdulmaged M Traish Journal: BMC Womens Health Date: 2006-09-13 Impact factor: 2.809